1921
Volume 102, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Hepatosplenic schistosomiasis (HSS) complicates portal hypertension, leading to life-threatening variceal bleeding. Variceal bleeding is associated with increased portal vein diameter (PVD). Beta-blockers prevent variceal bleeding. It is unclear whether beta-blockers such as propranolol can reduce PVD in HSS. We aimed to explore the effect of propranolol on PVD in HSS. A longitudinal study was conducted at the University Teaching Hospital, Zambia, as an extension of a clinical trial of rifaximin undertaken to test the hypothesis that rifaximin could reduce bacterial translocation in HSS. We randomized 85 adults to either rifaximin and standard care, or propranolol-based standard care only for 42 days. We then followed up all the patients on propranolol up to day 180. We used ultrasound to measure PVD at baseline and day 180. The primary outcome was reduction in PVD. Beta-blockade and splenic size reduction were secondary outcomes. Portal vein diameter reduced after 180 days of propranolol therapy from median 12 mm (interquartile range (IQR): 11–14) to median 10 mm (IQR: 9–13) ( < 0.001). The pulse rate reduced from baseline median 70 beats/minute (IQR: 66–80) to 65 beats/minute (IQR: 60–70) by day 180 ( = 0.006). Hemoglobin levels improved from baseline median 8 g/dL (IQR: 6–11) to 12 g/dL (10–14) ( < 0.001). Splenic size remained unchanged. Propranolol led to the reduction in PVD over 180 days. This suggests that ultrasound could be useful in monitoring response and compliance to beta-blockers, especially in resource-constraint areas where portal hypertension measurement facilities are unavailable.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0452
2020-02-17
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/4/tpmd190452.html?itemId=/content/journals/10.4269/ajtmh.19-0452&mimeType=html&fmt=ahah

References

  1. Watts C, 2017. Neglected tropical diseases: a DFID perspective. PLoS Negl Trop Dis 11: e0005492.
    [Google Scholar]
  2. Al-Busafi SA, Ghali P, Wong P, Deschenes M, 2012. Endoscopic management of portal hypertension. Int J Hepatol 2012: 203794.
    [Google Scholar]
  3. Payne L, Turner-Moss E, Mutengo M, Asombang AW, Kelly P, 2013. Prevalence of schistosome antibodies with hepatosplenic signs and symptoms among patients from Kaoma, western province, Zambia. BMC Res Notes 6: 344.
    [Google Scholar]
  4. Chipeta J, Mwansa J, Kachimba J, 2009. Schistosomiasis disease burden in Zambian children: time for affirmative action is now. Med J Zambia 36: 15.
    [Google Scholar]
  5. Mutengo MM, Mwansa JC, Mduluza T, Sianongo S, Chipeta J, 2014. High Schistosoma mansoni disease burden in a rural district of western Zambia. Am J Trop Med Hyg 91: 965972.
    [Google Scholar]
  6. Sinkala E, Kapulu MC, Besa E, Zyambo K, Chisoso NJ, Foster GR, Kelly P, 2016. Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis. Liver Int 36: 145150.
    [Google Scholar]
  7. Mugono M, Konje E, Kuhn S, Mpogoro FJ, Morona D, Mazigo HD, 2014. Intestinal schistosomiasis and geohelminths of Ukara Island, north-western Tanzania: prevalence, intensity of infection and associated risk factors among school children. Parasit Vectors 7: 612.
    [Google Scholar]
  8. Kabatereine NB, Brooker S, Tukahebwa EM, Kazibwe F, Onapa AW, 2004. Epidemiology and geography of Schistosoma mansoni in Uganda: implications for planning control. Trop Med Int Health 9: 372380.
    [Google Scholar]
  9. Worku L, Damte D, Endris M, Tesfa H, Aemero M, 2014. Schistosoma mansoni infection and associated determinant factors among school children in Sanja town, northwest Ethiopia. J Parasitol Res 2014: 792536.
    [Google Scholar]
  10. Ibrahim SZ, Arhab BM, Suleiman HS, Abdelwahab O, Elmari SH, Hassan AM, 2012. The natural history of bleeding oesophageal varices in patients with schistosomal portal hypertension. Khartoum Med J 3.
    [Google Scholar]
  11. Kheir MM, Eltoum IA, Saad AM, Ali MM, Baraka OZ, Homeida MM, 1999. Mortality due to schistosomiasis mansoni: a field study in Sudan. Am J Trop Med Hyg 60: 307310.
    [Google Scholar]
  12. Andrade ZA, 2004. Schistosomal hepatopathy. Mem Inst Oswaldo Cruz 99: 5157.
    [Google Scholar]
  13. Cerri G, Alves V, Magalhães A, 1984. Hepatosplenic Schistosomiasis mansoni: ultrasound manifestations. Radiology 153: 777780.
    [Google Scholar]
  14. Bezerra AS, D’Ippolito G, Caldana RP, Leopoldino DD, Batista GR, Borges DR, Lopes Filho Gde J, Ahmed M, 2008. Differentiating cirrhosis and chronic hepatosplenic schistosomiasis using MRI. Am J Roentgenol 190: W201W207.
    [Google Scholar]
  15. Strauss E, 2002. Hepatosplenic schistosomiasis: a model for the study of portal hypertension. Ann Hepatol 1: 611.
    [Google Scholar]
  16. Pinto-Silva RA, Abrantes WL, Antunes CM, Lambertucci JR, 1994. Sonographic features of portal hypertension in Schistosomiasis mansoni. Rev Inst Med Trop São Paulo 36: 355361.
    [Google Scholar]
  17. Addley J, Tham TC, Cash WJ, 2012. Use of portal pressure studies in the management of variceal haemorrhage. World J Gastr Endosc 4: 281.
    [Google Scholar]
  18. Garcia‐Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M, 1985. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5: 419424.
    [Google Scholar]
  19. Ripoll C et al., 2007. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133: 481488.
    [Google Scholar]
  20. Nedredal GI, Yin M, McKenzie T, Lillegard J, Luebke-Wheeler J, Talwalkar J, Ehman R, Nyberg SL, 2011. Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging 34: 7987.
    [Google Scholar]
  21. Rebouças G, 1975. Clinical aspects of hepatosplenic schistosomiasis: a contrast with cirrhosis. Yale J Biol Med 48: 369.
    [Google Scholar]
  22. Weinreb J, Kumari S, Phillips G, Pochaczevsky R, 1982. Portal vein measurements by real-time sonography. Am J Roentgenol 139: 497499.
    [Google Scholar]
  23. Kong DR, Ma C, Wang M, Wang JG, Chen C, Zhang L, Hao JH, Li P, Xu J, 2013. Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. World J Gastroenterol 19: 42284233.
    [Google Scholar]
  24. Burroughs AK, Jenkins WJ, Sherlock S, Dunk A, Walt RP, Osuafor TO, Mackie S, Dick R, 1983. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. New Engl J Med 309: 15391542.
    [Google Scholar]
  25. Funakoshi N, Ségalas-Largey F, Duny Y, Oberti F, Valats JC, Bismuth M, Daurès JP, Blanc P, 2010. Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 16: 59825992.
    [Google Scholar]
  26. Tourabi HE, Amin AA, Shaheen M, Woda SA, Homeida M, Harron DW, 1994. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol 88: 493500.
    [Google Scholar]
  27. Garcia-Tsao G, Bosch J, 2010. Management of varices and variceal hemorrhage in cirrhosis. New Engl J Med 362: 823832.
    [Google Scholar]
  28. Samanta T, Purkait R, Sarkar M, Misra A, Ganguly S, 2012. Effectiveness of beta blockers in primary prophylaxis of variceal bleeding in children with portal hypertension. Trop Gastroenterol 32: 299303.
    [Google Scholar]
  29. Farias AQ, Kassab F, da Rocha EC, Dos Santos Bomfim V, Vezozzo DC, Bittencourt PL, Carrilho FJ, 2009. Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. J Gastroenterol Hepatol 24: 18521856.
    [Google Scholar]
  30. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG, 2008. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 48 (Suppl 1): 6892.
    [Google Scholar]
  31. Levitt DG, Levitt MD, 2012. Quantitative modeling of the physiology of ascites in portal hypertension. BMC Gastroenterol 12: 26.
    [Google Scholar]
  32. Prata A, Ruiz-Guevara R, Antunes CM, Marinho CC, Queiroz LC, Voieta I, Lambertucci JR, 2010. Comparison between clinical and ultrasonographic findings in cases of periportal fibrosis in an endemic area for Schistosomiasis mansoni in Brazil. Rev Soc Bras Med Trop 43: 129134.
    [Google Scholar]
  33. Leite LA, Domingues AL, Lopes EP, Ferreira R C, Filho PA, da Fonseca CS, Dos Santos BS, Lima VL, 2013. Relationship between splenomegaly and hematologic findings in patients with hepatosplenic schistosomiasis. Rev Bras Hematol Hemoter 35: 332336.
    [Google Scholar]
  34. Leite LA, Pimenta Filho AA, Ferreira R C, da Fonseca CS, dos Santos BS, Montenegro SM, Lopes EP, Domingues AL, Owen JS, Lima VL, 2015. Splenectomy improves hemostatic and liver functions in hepatosplenic Schistosomiasis mansoni. PLoS One 10: e0135370.
    [Google Scholar]
  35. Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A, 2015. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 21: 1232212333.
    [Google Scholar]
  36. Taylor DN, McKenzie R, Durbin A, Carpenter C, Haake R, Bourgeois A, 2008. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 52: 11791181.
    [Google Scholar]
  37. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG, 2009. Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis. Aliment Pharmacol Ther 29: 992999.
    [Google Scholar]
  38. Liew E, Sutherland T, Slavin J, Darby J, 2011. Isolated periportal tuberculosis causing portal vein thrombosis. J Ultrasound Med 30: 15991601.
    [Google Scholar]
  39. Medhat A, Nafeh M, Swifee Y, Helmy A, Zaki S, Shehata M, Ibrahim S, Abdel-Kader DA, Strickland GT, 1998. Ultrasound-detected hepatic periportal thickening in patients with prolonged pyrexia. Am J Trop Med Hyg 59: 4548.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0452
Loading
/content/journals/10.4269/ajtmh.19-0452
Loading

Data & Media loading...

  • Received : 14 Jun 2019
  • Accepted : 27 Aug 2019
  • Published online : 17 Feb 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error